Resolution of Vitreomacular Traction Using Jetrea and its Potential Role in Diabetic Macular Edema
505 edema; 585 macula/fovea; 763 vitreous; Ophthalmology
Oneill B; Shah A; Coney J M
Investigative Ophthalmology & Visual Science
2014
2014-04
Journal Article
n/a
Evaluation of Visual Acuity and Acute Retinal Changes Following Intravitreal Injection of Ocriplasmin
Ophthalmology
Patel D; Shah A; Melchioris A; Miller D G
Investigative Ophthalmology & Visual Science
2017
2017-06
Journal Article
n/a
Prevalence of CFH and ARMS2 Genetic Polymorphisms in African-American Patients with Age-Related Macular Degeneration
Ophthalmology
Shah A; Singerman L J; Zanke B
Investigative Ophthalmology & Visual Science
2015
2015-06
Journal Article
n/a
The incidence of COVID-19 in patients with metabolic syndrome and non-alcoholic steatohepatitis: A population-based study.
Metabolic syndrome; Obesity; Diabetes mellitus; COVID-19; African American; Non-alcoholic steatohepatitis
BACKGROUND: The novel coronavirus disease (COVID-19) emerged from China in 2019 and rapidly spread worldwide. Patients with metabolic comorbid conditions are more susceptible to infection by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Metabolic syndrome is a constellation of interlinked metabolic risk factors that predispose patients to increased risk of complications. Non-alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of metabolic syndrome and non-alcoholic steatohepatitis (NASH) is the aggressive form of NAFLD. OBJECTIVE: The aim of this study is to determine the relationship between metabolic syndrome components and the risk of COVID-19. METHODS: We reviewed data from a large commercial database (Explorys IBM) that aggregates electronic health records from 26 large nationwide healthcare systems. Using systemized nomenclature of clinical medical terms (SNOMED-CT), we identified adults with the diagnosis of metabolic syndrome and its individual components from 1999 to 2019. We included patients with the diagnosis of COVID-19 from December 2019 to May 2020. Comorbidities known to be associated with COVID-19 and metabolic syndrome such as obesity, diabetes mellitus, dyslipidemia, smoking, male gender, African American, and hypertension were collected. Univariable and multivariable analyses were performed to investigate whether metabolic syndrome or its individual components are independently associated with the risk of COVID-19. RESULTS: Out of 61.4 million active adult patients in the database, 8885 (0.01%) had documented COVID-19. The cumulative incidence of COVID-19 was higher if metabolic syndrome was the primary diagnosis (0.10% vs 0.01%, OR 7.00 [6.11-8.01]). The adjusted odds (aOR) of having COVID-19 was higher in patients if they were African Americans (aOR 7.45 [7.14-7.77]), hypertensive (aOR 2.53 [2.40-2.68]), obese (aOR 2.20 [2.10-2.32]), diabetic (aOR 1.41 [1.33-1.48]), hyperlipidemic (aOR 1.70 [1.56-1.74]), or diagnosed with NASH (aOR 4.93 [4.06-6.00]). There was a slight decrease in the adjusted odds of having COVID-19 in males as compared to females (aOR 0.88 [0.84-0.92]). CONCLUSION: The incidence of COVID-19 in patients with metabolic syndrome is high. Among all comorbid metabolic conditions, NASH had the strongest association with COVID-19.
Ghoneim S; Butt MU; Hamid O; Shah A; Asaad I
Metabolism Open
2020
2020-12
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
journalArticle
<a href="http://doi.org/10.1016/j.metop.2020.100057" target="_blank" rel="noreferrer noopener">10.1016/j.metop.2020.100057</a>